Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Drug Combinations in Recurrent Glioblastoma (ISM-GBM)
NCT05043701Phase 1Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioblastoma (GBM), sponsored by Oslo University Hospital. Primary endpoint: Drug screen completion and treatment initiation at 8 weeks. Started Mar 2023; status: recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05043701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043701.